Spire Wealth Management bought a new position in Novavax, Inc. (NASDAQ:NVAX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange ...

Shares of Novavax Inc. NVAX slipped 1.69% to $8.13 Friday, on what proved to be an all-around poor trading session for the ...

The stock's fall snapped a two-day winning streak.

Novavax (NVAX) is one of the stocks most watched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Novavax (NVAX) closed at $8.19 in the latest trading session, marking a +0.74% move from the prior day. This move outpaced the S&P 500's daily gain of 0.67%. At the same time, the Dow added 0.38%, and ...

So, it's important to know a company's potential revenue growth. For Novavax, the consensus sales estimate for the current quarter of $90.72 million indicates a year-over-year change of -68.9%.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans.

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...